ITGAX and breast cancer: This resulted in a significant decrease of PB myeloid Lin-/HLA-DR+/CD11c+ DCs in breast cancer patients compared with control subjects (9.61±0.68 × 103 ml−1vs 14.80±0.95, P<0.001), while the number of PB plasmacytoid Lin-/HLA-DR+/CD123+ DCs was unaffected.